Table 1

Baseline characteristics of the patients (n=36) who received prednisolone 20 mg, prednisolone 40 mg or placebo for at least 1 week during a 2-week, randomised, double-blind, placebo-controlled trial

Screening parametersPlaceboPrednisolone 20 mgPrednisolone 50 mg
Number of patients, n131112
Age in years (mean±SD)43±1635±8.342±8.5
Disease duration (years± SD)16±1613±7.514±9.2
Gender (female %)23188
HLA-B27 positivity (%)917373
CRP mg/litre (mean±SD)27±2119±1332±47
CRP ≥10 mg/litre (%)776458
Patients with peripheral arthritis (n)231
Patients with enthesitis according to Berlin enthesitis score (n)255
Patients with IBD (n)011
Patients with psoriasis (n)002
Patients with history of uveitis (n)100
BASDAI morning stiffness (mean±SD)6.8±2.57.1±2.37.0±1.6
BASFI (mean±SD)5.8±1.46.2±1.75.2±1.9
PG (mean±SD)7.2±1.67.9±1.37.4±2.1
Pain (mean±SD)7.6±1.68.1±1.07.6±1.8
BASMI (mean±SD)4.0±2.04.6±2.94.0±2.3
ASDAS (mean±SD)4.1±0.74.2±0.84.1±0.8
  • Baseline characteristics were not significantly different between the prednisolone and the placebo groups (Fisher's exact test, Wilcoxon test, significance level p=0.05).

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI morning stiffness, mean of BASDAI question 5 and 6 for morning stiffness; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein; HLA, human leukocyte antigen; IBD, inflammatory bowel disease; PG, patient global assessment.